MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer
Status: NO_LONGER_AVAILABLE
Study type: EXPANDED_ACCESS
Conditions: Advanced Hormone Receptor Positive (HR+) Breast Cancer
Interventions: DRUG: everolimus
Sponsor: Novartis Pharmaceuticals